Chengdu Huasun Bio-Tech

Chengdu Huasun Technology Group is a prominent Chinese biopharmaceutical company that specializes in the integration of modern biotechnology with Traditional Chinese Medicine (TCM). The company is best known for developing Licartin (Iodine[131I] Metuximab Injection), which is the world's first monoclonal antibody-based radioimmunotherapy for the treatment of primary hepatocellular carcinoma. Beyond oncology, Huasun maintains a strong market presence in the cardiovascular and cerebrovascular sectors with its proprietary TCM products, most notably the Sanqi Tongshu capsule. The company operates fully integrated R&D, GMP-certified manufacturing, and distribution networks. Headquartered in Chengdu and listed on the Shenzhen Stock Exchange, Huasun continues to focus on innovative biological drugs and standardized TCM formulations.